About Alladapt
Alladapt is a company based in Menlo Park (United States) founded in 2018 by Kari Nadeau. Alladapt has raised $179 million across 3 funding rounds from investors including Novartis, Hercules Capital and Enavate Sciences. The company has 1 employees. Alladapt operates in a competitive market with competitors including PureTech Health, Dren Bio, Adagene, Stallergenes Greer and IgGenix, among others.
- Headquarter Menlo Park, United States
- Employees 1
- Founders Kari Nadeau
- SectorsHealthcare
- Phone•••• ••••
- Website alladapt.com
- Social LinkedIn X
- Legal Name Alladapt Immunotherapeutics, Inc.
- Total Equity Funding$179M (USD)
in 3 rounds
- InvestorsNovartis
& 6 more
- Employee Count1
Funding Insights of Alladapt
Alladapt has successfully raised a total of $179M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $179M
- Total Rounds 3
- First Round $60M
(Feb 2020)
- Investors Count 7
All 3 funding rounds of Alladapt with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | – | Debt – Conventional | – | – | |
| Jun 2022 | $119M | Series D | – | Enavate Sciences | |
| Feb 2020 | $60M | Series C | – | Gurnet Point Capital | – |
7 investors in total: 7 institutional.
Investors in Alladapt
Alladapt has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Hercules Capital and Enavate Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Investment partnerships are built and principal investments are made by B-FLEXION. | – | gurnetpointcapital.com | - | |
Venture capital investments are focused on food allergy solutions. | 2020 | allerfund.com | - | |
Investments are focused across multiple sectors by the firm. | – | wrg.vc | Seattle, United States | |
Red Tree Venture Capital is focused on life science investments. | – | redtreevc.com | Redwood City, United States | |
Drug discovery, development, and market assessment consulting services are provided. | 2022 | enavatesciences.com | United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Alladapt
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alladapt
9 people are tracked at Alladapt (4 in leadership, 4 in board & advisors, 1 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Kari Nadeau | Co-Founder | Leadership |
Louise Peacock | Chief Regulatory Affairs & Quality Officer | Leadership |
Sid Reddy | Executive Director of Finance, Controller | Leadership |
George Gindoyan | Head Of IT & Business Operations | Leadership |
Jim Momtazee | Board Member | Board & advisors |
Travis Wilson | Board Member | Board & advisors |
George Montgomery | Board Member | Board & advisors |
Stacey Seltzer | Board Member | Board & advisors |
Amy Sullivan | SVP, Development Operations | Team |
Complete people profiles for Alladapt
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alladapt
3 dated milestones of Alladapt across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Alladapt is founded.
- Funding First funding round of $60.0M.
- Funding Latest funding round, Debt – Conventional,.
Competitors of Alladapt
Alladapt operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PureTech Health, Dren Bio, Adagene, Stallergenes Greer and IgGenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| drenbio.com | 2019 | San Carlos, United States | $131M | – | Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases. | |
| adagene.com | 2012 | Suzhou, China | $155M | – | Immunotherapy antibodies for cancer treatment are developed. | |
| stallergenesgreer.com | 2013 | London, United Kingdom | – | 115,499 | Allergen immunotherapies for respiratory allergies are developed. | |
| iggenix.com | 2019 | San Francisco, United States | $75M | – | Therapeutic solutions for food allergies are developed via antibody platforms. | |
| torlbio.com | 2019 | Los Angeles, United States | $412.3M | – | Antibody-based therapeutics are developed for cancer treatment. |
Detailed competitors of Alladapt
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alladapt
Complete news archive for Alladapt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Alladapt
10 companies that operate in the same segment as Alladapt (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Alladapt
Alladapt was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Alladapt is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Alladapt is a funded company, having raised a total of $179M across 3 funding rounds to date. The company's 1st funding round was a Series C of $60M, raised on Feb 2020.
Alladapt has 1 employees.
Alladapt was founded in 2018 and is based in Menlo Park, United States. Therapeutics are developed by the company for the treatment of food allergies, including a single investigational oral immunotherapy known as ADP101. This approach targets common allergens such as cows milk, eggs, tree nuts, peanuts, and shellfish. Prescription options are offered to manage a broad spectrum of food-related sensitivities in the biotechnology sector.
Alladapt's top competitors include Dren Bio, PureTech Health and Adagene.
Alladapt has 7 investors. Key investors include Novartis, Hercules Capital, Enavate Sciences, B-FLEXION, and AllerFund.
Alladapt operates through Alladapt Immunotherapeutics, Inc..